For the quarter ending 2026-03-31, CNMD had -$5,787K decrease in cash & cash equivalents over the period. $10,580K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net income | 13,828 | 16,739 | 30,316 |
| Depreciation | 4,174 | 4,066 | 13,077 |
| Amortization of deferred debt issuance costs | 1,276 | 1,539 | 4,107 |
| Amortization | 14,663 | 14,784 | 42,354 |
| Stock-based compensation | 5,502 | 4,971 | 23,352 |
| Deferred income taxes | 1,535 | 812 | 2,711 |
| Gain on sale of a product line | -3,916 | - | - |
| Non-cash adjustments to fair value of contingent consideration liability | 722 | 19,447 | 3,504 |
| Loss on early extinguishment of debt | - | 0 | 363 |
| Accounts receivable | -18,606 | 22,671 | -20,310 |
| Inventories | 12,269 | -8,509 | 15,242 |
| Accounts payable | 10,480 | -13,612 | 3,863 |
| Income taxes | - | -558 | - |
| Accrued compensation and benefits | -21,153 | 5,923 | 8,990 |
| Other assets | 17,215 | 225 | 12,934 |
| Other liabilities | -2,761 | 6,611 | -417 |
| Net cash provided by operating activities | 13,472 | 46,335 | 124,354 |
| Proceeds from sale of a product line | -7,000 | - | - |
| Purchases of property, plant and equipment | 2,892 | 5,111 | 14,695 |
| Other | 0 | 2,000 | -850 |
| Net cash provided by (used in) investing activities | 4,108 | -7,111 | -13,845 |
| Payments on term loan | 0 | 20,000 | 79,821 |
| Proceeds from term loan | - | 0 | 25,234 |
| Payments on revolving line of credit | 155,000 | 187,000 | 508,432 |
| Proceeds from revolving line of credit | 180,000 | 187,000 | 508,432 |
| Payments to redeem convertible notes | - | 0 | 0 |
| Repurchases of common stock | 37,017 | - | - |
| Payments related to contingent consideration | 11,364 | 11,183 | 22,577 |
| Payments related to debt issuance costs | - | 0 | 2,897 |
| Dividends paid on common stock | 0 | 6,191 | 18,555 |
| Other, net | 828 | 4 | 166 |
| Net cash used in financing activities | -22,553 | -37,370 | -98,450 |
| Effect of exchange rate changes on cash and cash equivalents | -814 | 34 | 2,411 |
| Net increase (decrease) in cash and cash equivalents | -5,787 | 1,888 | 14,470 |
| Cash and cash equivalents at beginning of period | 40,817 | 38,929 | 24,459 |
| Cash and cash equivalents at end of period | 35,030 | 40,817 | 38,929 |
CONMED Corp (CNMD)
CONMED Corp (CNMD)